The Nucleocapsid Protein of Rift Valley Fever Virus Is a Potent Human CD8+ T Cell Antigen and Elicits Memory Responses

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Xu, Weidong ^a   Watts, Douglas M ^a   Costanzo, Margaret C ^a   Tang, Xiaolei ^a   Venegas, Leon A ^a   Jiao, Feng ^a   Sette, Alessandro ^b   Sidney, John ^b   Sewell, Andrew K ^c   Wooldridge, Linda ^c   Makino, Shinji ^d   Morrill, John C ^d   Peters, Clarence J ^d   Kan Mitchell, June ^a  

^a UNIVERSITY OF TEXAS AT EL PASO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; EPITOPE; HLA ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 9; LIVE VACCINE; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; T LYMPHOCYTE ANTIGEN; TETRAMER; VIRUS PROTEIN; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; IMMUNE RESPONSE; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MEMORY; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RIFT VALLEY FEVER; RIFT VALLEY FEVER BUNYAVIRUS;

AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSPOT ASSAY; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; GENETIC VECTORS; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; LENTIVIRUS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; NUCLEOCAPSID PROTEINS; RIFT VALLEY FEVER VIRUS; VIRAL VACCINES;

EID: 84875063702     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059210     Document Type: Article

References (86)

1. Boshra H, Lorenzo G, Busquets N, Brun A, (2011) Rift valley fever: recent insights into pathogenesis and prevention. J Virol 85: 6098-6105.
2. Schwentker FF, Rivers TM, (1934) Rift Valley Fever in Man: Report of a Fatal Laboratory Infection Complicated by Thrombophlebitis. The Journal of experimental medicine 59: 305-313.
3. Francis T, Magill TP, (1935) Rift Valley Fever: A Report of Three Cases of Laboratory Infection and the Experimental Transmission of the Disease to Ferrets. The Journal of experimental medicine 62: 433-448.
4. Smithburn KC, Mahaffy AF, Haddow AJ, Kitchen SF, Smith JF, (1949) Rift Valley fever; accidental infections among laboratory workers. J Immunol 62: 213-227.
5. Adam AA, Karsany MS, Adam I, (2010) Manifestations of severe Rift Valley fever in Sudan. Int J Infect Dis 14: e179-180.
6. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J, (2010) Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res 41: 61.
7. Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, et al. (2002) Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA: the journal of the American Medical Association 287: 2391-2405.
8. Ikegami T, Makino S, (2009) Rift valley fever vaccines. Vaccine 27Suppl 4: D69-72.
9. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, et al. (1999) Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year experience. Vaccine 18: 181-189.
10. Muller R, Saluzzo JF, Lopez N, Dreier T, Turell M, et al. (1995) Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 53: 405-411.
11. Caplen H, Peters CJ, Bishop DH, (1985) Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66 (Pt 10): 2271-2277.
12. Dungu B, Louw I, Lubisi A, Hunter P, von Teichman BF, et al. (2010) Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 28: 4581-4587.
13. Morrill JC, Carpenter L, Taylor D, Ramsburg HH, Quance J, et al. (1991) Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine 9: 35-41.
14. Morrill JC, Mebus CA, Peters CJ, (1997) Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 58: 1104-1109.
15. Morrill JC, Mebus CA, Peters CJ, (1997) Safety of a mutagen-attenuated Rift Valley fever virus vaccine in fetal and neonatal bovids. Am J Vet Res 58: 1110-1114.
16. Morrill JC, Peters CJ, (2011) Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine. J Infect Dis 204: 617-625.
17. Morrill JC, Peters CJ, (2003) Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys. Vaccine 21: 2994-3002.
18. Kark JD, Aynor Y, Peters CJ, (1982) A rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol 116: 808-820.
19. Metwally S (2008) Foreign Animal Diseases.; Brown C, Torres, A., editor. Boca Raton, FL: Boca Publications Group, Inc.
20. Habjan M, Penski N, Spiegel M, Weber F, (2008) T7 RNA polymerase-dependent and-independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol 89: 2157-2166.
21. Ikegami T, Won S, Peters CJ, Makino S, (2006) Rescue of infectious rift valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 80: 2933-2940.
22. Heise MT, Whitmore A, Thompson J, Parsons M, Grobbelaar AA, et al. (2009) An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect: 1-10.
23. Pichlmair A, Habjan M, Unger H, Weber F, (2010) Virus-like particles expressing the nucleocapsid gene as an efficient vaccine against Rift Valley fever virus. Vector Borne Zoonotic Dis 10: 701-703.
24. van Vuren PJ, Tiemessen CT, Paweska JT, (2010) Evaluation of a Recombinant Rift Valley Fever Virus Subunit Nucleocapsid Protein as an Immunogen in Mice and Sheep. The Open Vaccine Journal 3: 114-126.
25. van Vuren JP, Potgieter AC, Paweska JT, van Dijk AA, (2007) Preparation and evaluation of a recombinant Rift Valley fever virus N protein for the detection of IgG and IgM antibodies in humans and animals by indirect ELISA. J Virol Methods 140: 106-114.
26. Paweska JT, Jansen van Vuren P, Swanepoel R, (2007) Validation of an indirect ELISA based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection of IgG antibody in humans. J Virol Methods 146: 119-124.
27. Fafetine JM, Tijhaar E, Paweska JT, Newes LCBG, Hendriks J, et al. (2007) Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N-protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Veterinary Microbiology 121: 29-38.
28. Williams R, Ellis CE, Smith SJ, Potgieter CA, Wallace D, et al. (2011) Validation of an IgM antibody capture ELISA based on a recombinant nucleoprotein for identification of domestic ruminants infected with Rift Valley fever virus. J Virol Methods 177: 140-146.
29. Wallace DB, Ellis CE, Espach A, Smith SJ, Greyling RR, et al. (2006) Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24: 7181-7189.
30. van Vuren PJ, Tiemessen CT, Paweska JT, (2011) Anti-nucleocapsid protein immune responses counteract pathogenic effects of Rift Valley fever virus infection in mice. PLoS One 6: e25027.
31. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, Ahlm C, et al. (2009) Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 6: 6.
32. Lorenzo G, Martin-Folgar R, Rodriguez F, Brun A, (2008) Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26: 5255-5262.
33. Lorenzo G, Martin-Folgar R, Hevia E, Boshra H, Brun A, (2010) Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR(-/-) mice induced by different DNA vaccination regimens. Vaccine 28: 2937-2944.
34. Boshra H, Lorenzo G, Rodriguez F, Brun A (2011) A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR(-/-) mice upon lethal virus challenge. Vaccine.
35. Harty JT, Badovinac VP, (2008) Shaping and reshaping CD8+ T-cell memory. Nat Rev Immunol 8: 107-119.
36. Kan-Mitchell J, Bisikirska B, Wong-Staal F, Schaubert KL, Bajcz M, et al. (2004) The HIV-1 HLA-A2-SLYNTVATL is a help-independent CTL epitope. J Immunol 172: 5249-5261.
37. Kan-Mitchell J, Bajcz M, Schaubert KL, Price DA, Brenchley JM, et al. (2006) Degeneracy and repertoire of the human HIV-1 Gag p17(77-85) CTL response. J Immunol 176: 6690-6701.
38. Schaubert KL, Price DA, Frahm N, Li J, Ng HL, et al. (2007) Availability of a diversely avid CD8+ T cell repertoire specific for the subdominant HLA-A2-restricted HIV-1 Gag p2419-27 epitope. J Immunol 178: 7756-7766.
39. Salter RD, Cresswell P, (1986) Impaired assembly and transport of HLA-A and-B antigens in a mutant TxB cell hybrid. Embo J 5: 943-949.
40. Purbhoo MA, Boulter JM, Price DA, Vuidepot AL, Hourigan CS, et al. (2001) The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 276: 32786-32792.
41. Sidney J, Southwood S, Mann DL, Fernandez-Vina MA, Newman MJ, et al. (2001) Majority of peptides binding HLA-A*0201 with high affinity crossreact with other A2-supertype molecules. Hum Immunol 62: 1200-1216.
42. Wooldridge L, van den Berg HA, Glick M, Gostick E, Laugel B, et al. (2005) Interaction between the CD8 coreceptor and major histocompatibility complex class I stabilizes T cell receptor-antigen complexes at the cell surface. J Biol Chem 280: 27491-27501.
43. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, et al. (1994) Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1: 751-761.
44. Morrill JC, Peters CJ, (2011) Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent rift valley fever virus. J Infect Dis 204: 229-236.
45. Gruber A, Kan-Mitchell J, Kuhen KL, Mukai T, Wong-Staal F, (2000) Dendritic cells transduced by multiply deleted HIV-1 vectors exhibit normal phenotypes and functions and elicit an HIV-specific cytotoxic T-lymphocyte response in vitro. Blood 96: 1327-1333.
46. Sidney J, Southwood S, Oseroff C, Del Guercio MF, Sette A, et al. (1998) Measurement of MHC/peptide interactions by gel filtration Current protocols in immunology: Wiley, New York. pp. pp 18.13.11-18.13.19.
47. Schaubert KL, Price DA, Salkowitz JR, Sewell AK, Sidney J, et al. (2010) Generation of robust CD8(+) T-cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. Eur J Immunol 40: 1950-1962.
48. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781-4789.
49. Makedonas G, Hutnick N, Haney D, Amick AC, Gardner J, et al. (2010) Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells. PLoS Pathog 6: e1000798.
50. Kern F, LiPira G, Gratama JW, Manca F, Roederer M, (2005) Measuring Ag-specific immune responses: understanding immunopathogenesis and improving diagnostics in infectious disease, autoimmunity and cancer. Trends Immunol 26: 477-484.
51. Seder RA, Darrah PA, Roederer M, (2008) T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 8: 247-258.
52. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. (2003) Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 281: 65-78.
53. La Rosa C, Wang Z, Brewer JC, Lacey SF, Villacres MC, et al. (2002) Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice. Blood 100: 3681-3689.
54. Varadarajan N, Julg B, Yamanaka YJ, Chen H, Ogunniyi AO, et al. (2011) A high-throughput single-cell analysis of human CD8(+) T cell functions reveals discordance for cytokine secretion and cytolysis. J Clin Invest 121: 4322-4331.
55. Sette A, Vitiello A, Reherman B, Fowler P, Nayersina R, et al. (1994) The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol 153: 5586-5592.
56. Moutaftsi M, Salek-Ardakani S, Croft M, Peters B, Sidney J, et al. (2009) Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model. Eur J Immunol 39: 717-722.
57. Fruci D, Lauvau G, Saveanu L, Amicosante M, Butler RH, et al. (2003) Quantifying recruitment of cytosolic peptides for HLA class I presentation: impact of TAP transport. J Immunol 170: 2977-2984.
58. Thirdborough SM, Roddick JS, Radcliffe JN, Howarth M, Stevenson FK, et al. (2008) Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide-MHC class I complexes. Eur J Immunol 38: 364-369.
59. Obar JJ, Khanna KM, Lefrancois L, (2008) Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity 28: 859-869.
60. Ertelt JM, Johanns TM, Mysz MA, Nanton MR, Rowe JH, et al. (2011) Selective culling of high avidity antigen-specific CD4+ T cells after virulent Salmonella infection. Immunology 134: 487-497.
61. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, Freiberg AN, et al. (2010) A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge. Virology 397: 187-198.
62. Koup RA, Douek DC, (2011) Vaccine design for CD8 T lymphocyte responses. Cold Spring Harb Perspect Med 1: a007252.
63. Hillaire ML, Osterhaus AD, Rimmelzwaan GF, (2011) Induction of virus-specific cytotoxic T lymphocytes as a basis for the development of broadly protective influenza vaccines. J Biomed Biotechnol 2011: 939860.
64. Valkenburg SA, Rutigliano JA, Ellebedy AH, Doherty PC, Thomas PG, et al. (2011) Immunity to seasonal and pandemic influenza A viruses. Microbes Infect 13: 489-501.
65. Wraith DC, Vessey AE, Askonas BA, (1987) Purified influenza virus nucleoprotein protects mice from lethal infection. J Gen Virol 68 (Pt 2): 433-440.
66. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404-5410.
67. Plotkin SA, (2010) Correlates of protection induced by vaccination. Clinical and vaccine immunology: CVI 17: 1055-1065.
68. Burton DR, (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706-713.
69. Amanna IJ, Slifka MK, (2011) Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 411: 206-215.
70. Greenbaum J, Sidney J, Chung J, Brander C, Peters B, et al. (2011) Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. Immunogenetics.
71. Raymond DD, Piper ME, Gerrard SR, Smith JL, (2010) Structure of the Rift Valley fever virus nucleocapsid protein reveals another architecture for RNA encapsidation. Proc Natl Acad Sci U S A 107: 11769-11774.
72. Schmaljohn CS, Hooper JW (2001) Bunyaviridae: the viruses and their replication. In: Knipe DM, Howley, P., Griffin, D E., Martin M A., Lamb R A., Roizman B., and Straus S E., editor. Fields Virology, 4th ed. Philadelphia, PA: Lippincott, Williams & Wilkins.
73. Paweska JT, van Vuren PJ, Kemp A, Buss P, Bengis RG, et al. (2008) Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo. Vet Microbiol 127: 21-28.
74. Martin-Folgar R, Lorenzo G, Boshra H, Iglesias J, Mateos F, et al. (2010) Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization. mAbs 2: 275-284.
75. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD, (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176.
76. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85: 5027-5035.
77. LaMere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331-4339.
78. Ronnblom L, (2011) The type I interferon system in the etiopathogenesis of autoimmune diseases. Ups J Med Sci 116: 227-237.
79. Colonna M, Trinchieri G, Liu YJ, (2004) Plasmacytoid dendritic cells in immunity. Nat Immunol 5: 1219-1226.
80. Besselaar TG, Blackburn NK, (1991) Topological mapping of antigenic sites on the Rift Valley fever virus envelope glycoproteins using monoclonal antibodies. Arch Virol 121: 111-124.
81. Nderitu L, Lee JS, Omolo J, Omulo S, O'Guinn ML, et al. (2011) Sequential rift valley Fever outbreaks in eastern Africa caused by multiple lineages of the virus. J Infect Dis 203: 655-665.
82. Ikegami T, (2012) Molecular biology and genetic diversity of Rift Valley fever virus. Antiviral Res 95: 293-310.
83. Hanke T, McMichael AJ, (2011) HIV-1: from escapism to conservatism. European journal of immunology 41: 3390-3393.
84. McMichael AJ, Hanke T, (2003) HIV vaccines 1983-2003. Nat Med 9: 874-880.
85. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, Ferrari G, Giorgi E, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 206: 1253-1272.
86. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, et al. (2012) Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 18: 274-280.